Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180513 | 0.82 | — | — | |
| SCHEMBL1763594 | 0.80 | PKM (0.33) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL3883160 | 0.79 | DGAT1 (0.37) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL2215241 | 0.77 | GRM5 (0.37) | HSD17B10 | |
| SCHEMBL12502896 | 0.77 | KDM4E (0.36) | — | |
| SCHEMBL12502735 | 0.77 | — | — | |
| SCHEMBL1180521 | 0.77 | GRM5 (0.33) | — | |
| SCHEMBL6777096 | 0.75 | — | — | |
| SCHEMBL155502 | 0.75 | HRH3 (0.31) | — | |
| SCHEMBL7264954 | 0.74 | MAPT (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014022377-A1 | MEMBRANES AND COATINGS MADE FROM MIXTURES INCLUDING IONIC LIQUIDS HAVING SILICON-BONDED HYDROLYZABLE GROUPS | DOW CORNING CORPORATION (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20090220457-A1 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV IRES INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | PTC THERAPEUTICS, INC. | 2009-09-03 | — | — | US | disclosed |
| EP-1123296-B1 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-6333330-B1 | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220457-A1 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV IRES INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO | RNASE1, ERAP1, PREP | NPC1 928/4885RAB9A 2666/4885SMN1; SMN2 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.